FDA DEVICE FACTS
HardyDisk AST Ceftazidime/Avibactam, (30/20ug)-CZA50
Hardy Diagnostics
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
Use of HardyDisk AST Ceftazidime/Avibactam, (30/20ug) - CZA50, for in vitro agar diffusion susceptibility testing is indicated when there is need to determine the susceptibility of bacteria to Ceftazidime/Avibactam.
The concentration of Ceftazidime/Avibactam, (30/20ug) - CZA50, has been shown to be active against susceptible isolates of the following microorganisms with in vitro use: Morganella morganii, Providencia rettgeri, and Serratia marcescens.
The concentration of Ceftazidime/Avibactam, (30/2011g) - CZA50, has been shown to be active against susceptible isolates of the following microorganisms with both in vitro and in clinical infections: Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Providencia stuartii, Pseudomonas aeruginosa, Citrobacter freundii, Citrobacter koseri, Proteus spp., and Enterobacter aerogenes.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。